Clinical trial results:
A 12 Week Randomized, Double-Blind, Double-Dummy, Parallel Group, Active and Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety Profile of PF-06650833 in Subjects With Active Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Summary

EudraCT number	2016-002337-30
Trial protocol	BG DE HU CZ SK ES HR
Global end of trial date	15 August 2018

Results information

Result version number	v1 (current)
This version publication date	21 August 2019
First version publication date	21 August 2019

Trial information

Trial identification

Sponsor protocol code	B7921005

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02996500
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final

Date of interim/final analysis	15 July 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 August 2018
Global end of trial reached?	Yes
Global end of trial date	15 August 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of PF-06650833 at 12 weeks, in subjects with moderately severely active rheumatoid arthritis who had had an inadequate response to methotrexate.

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial subjects.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 November 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Slovakia: 12
Country: Number of subjects enrolled	Spain: 7
Country: Number of subjects enrolled	Taiwan: 3
Country: Number of subjects enrolled	Ukraine: 19
Country: Number of subjects enrolled	United States: 15
Country: Number of subjects enrolled	Australia: 3
Country: Number of subjects enrolled	Bosnia and Herzegovina: 21
Country: Number of subjects enrolled	Bulgaria: 15
Country: Number of subjects enrolled	Croatia: 2
Country: Number of subjects enrolled	Czech Republic: 3
Country: Number of subjects enrolled	Georgia: 33
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Hungary: 17
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Mexico: 11
Country: Number of subjects enrolled	Poland: 37
Country: Number of subjects enrolled	Romania: 7
Country: Number of subjects enrolled	Russian Federation: 23
Country: Number of subjects enrolled	Serbia: 33
Worldwide total number of subjects	269
EEA total number of subjects	103

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	232
From 65 to 84 years	37
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 669 subjects were screened, 269 subjects were assigned to and treated with: placebo (39 subjects), PF-06650833 (187 subjects), or tofacitinib (43 subjects). Of the 269 subjects, 237 subjects completed the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Subjects received 4 matching PF-06650833 modified release (MR) placebo tablets once daily (QD) and 1 matching tofacitinib placebo tablet twice a day (BID) in 12 weeks treatment period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Four matching PF-06650833 MR placebo tablets were administrated QD and 1 matching tofacitinib placebo tablet was administrated BID in 12 weeks treatment period.

Arm title	Tofa 10 mg

Arm description:

Subjects received 4 matching PF-06650833 MR placebo tablets QD and 1 tofacitinib 5 mg tablet BID in 12 weeks treatment period.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Four matching PF-06650833 MR placebo tablets were administrated QD in 12 weeks treatment period.

Investigational medicinal product name	Tofacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

One tofacitinib 5 mg tablet was administrated BID in 12 weeks treatment period.

Arm title	PF-06650833 20 mg

Arm description:

Subjects received 1 MR tablet of PF-06650833 20 mg and 3 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Three matching PF-06650833 MR placebo tablets were administrated QD and 1 matching tofacitinib placebo tablet was administrated BID in 12 weeks treatment period.

Investigational medicinal product name	PF-06650833
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

One MR tablet of PF-06650833 20 mg was administrated QD in 12 weeks treatment period.

Arm title	PF-06650833 60 mg

Arm description:

Subjects received 3 MR tablets of PF-06650833 20 mg and 1 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

One matching PF-06650833 MR placebo tablets was administrated QD and 1 matching tofacitinib placebo tablet was administrated BID in 12 weeks treatment period.

Investigational medicinal product name	PF-06650833
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Three MR tablets of PF-06650833 20 mg were administrated QD in 12 weeks treatment period.

Arm title	PF-06650833 200 mg

Arm description:

Subjects received 2 MR tablets of PF-06650833 100 mg and 2 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Arm type	Experimental

Investigational medicinal product name	PF-06650833
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Two MR tablets of PF-06650833 100 mg were administrated QD in 12 weeks treatment period.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Two matching PF-06650833 MR placebo tablets were administrated QD and 1 matching tofacitinib placebo tablet was administrated BID in 12 weeks treatment period.

Arm title	PF-06650833 400 mg

Arm description:

Subjects received 4 MR tablets of PF-06650833 100 mg QD and 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

One matching tofacitinib placebo tablet was administrated BID in 12 weeks treatment period.

Investigational medicinal product name	PF-06650833
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

Four MR tablets of PF-06650833 100 mg were administrated QD in 12 weeks treatment period.

Number of subjects in period 1	Placebo	Tofa 10 mg	PF-06650833 20 mg
Started	39	43	39
Completed	31	42	29
Not completed	8	1	10
Protocol deviation	-	-	-
Lack of efficacy	-	-	-
Non-Compliance With Study Drug	-	-	-
No Longer Meets Eligibility Criteria	-	-	1
Adverse event, non-fatal	1	1	4

Progressive Disease	1	-	-
Consent withdrawn by subject	3	-	3
Unspecified	2	-	2
Lost to follow-up	1	-	-

Number of subjects in period 1	PF-06650833 60 mg	PF-06650833 200 mg	PF-06650833 400 mg
Started	50	50	48
Completed	46	45	44
Not completed	4	5	4
Protocol deviation	1	-	-
Lack of efficacy	-	2	-
Non-Compliance With Study Drug	-	-	1
No Longer Meets Eligibility Criteria	-	-	-
Adverse event, non-fatal	3	1	2
Progressive Disease	-	-	-
Consent withdrawn by subject	-	2	-
Unspecified	-	-	-
Lost to follow-up	-	-	1

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Subjects received 4 matching PF-06650833 modified release (MR) placebo tablets once daily (QD) and 1 matching tofacitinib placebo tablet twice a day (BID) in 12 weeks treatment period.	
Reporting group title	Tofa 10 mg
Reporting group description:	
Subjects received 4 matching PF-06650833 MR placebo tablets QD and 1 tofacitinib 5 mg tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 20 mg
Reporting group description:	
Subjects received 1 MR tablet of PF-06650833 20 mg and 3 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 60 mg
Reporting group description:	
Subjects received 3 MR tablets of PF-06650833 20 mg and 1 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 200 mg
Reporting group description:	
Subjects received 2 MR tablets of PF-06650833 100 mg and 2 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 400 mg
Reporting group description:	
Subjects received 4 MR tablets of PF-06650833 100 mg QD and 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	

Reporting group values	Placebo	Tofa 10 mg	PF-06650833 20 mg
Number of subjects	39	43	39
Age, Customized Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age <37 wks)	0	0	0
Newborns(0-27 days)	0	0	0
Infants and toddlers(28 days - 23 months)	0	0	0
Children(2-11 years)	0	0	0
Adolescents(12-17 years)	0	0	0
Adults(18-64 years)	33	38	32
Adults(65-84 years)	6	5	7
Adults(85 years and over)	0	0	0
Age Continuous Units: Years			
arithmetic mean	54.9	52.7	55.9
standard deviation	± 10.51	± 10.02	± 9.74
Sex: Female, Male Units: Subjects			
Female	30	31	31
Male	9	12	8

Race/Ethnicity, Customized Units: Subjects			
White	37	43	37
Black or African American	0	0	0
Asian	2	0	1
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Other	0	0	1

Reporting group values	PF-06650833 60 mg	PF-06650833 200 mg	PF-06650833 400 mg
Number of subjects	50	50	48
Age, Customized Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age <37 wks)	0	0	0
Newborns(0-27 days)	0	0	0
Infants and toddlers(28 days - 23 months)	0	0	0
Children(2-11 years)	0	0	0
Adolescents(12-17 years)	0	0	0
Adults(18-64 years)	44	43	42
Adults(65-84 years)	6	7	6
Adults(85 years and over)	0	0	0
Age Continuous Units: Years			
arithmetic mean	51.0	53.6	54.8
standard deviation	± 12.05	± 11.47	± 8.76
Sex: Female, Male Units: Subjects			
Female	42	39	37
Male	8	11	11
Race/Ethnicity, Customized Units: Subjects			
White	47	47	43
Black or African American	0	0	0
Asian	1	2	2
American Indian or Alaska Native	1	1	0
Native Hawaiian or Other Pacific Islander	0	0	0
Other	1	0	3

Reporting group values	Total		
Number of subjects	269		
Age, Customized Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age <37 wks)	0		
Newborns(0-27 days)	0		
Infants and toddlers(28 days - 23 months)	0		

Children(2-11 years)	0		
Adolescents(12-17 years)	0		
Adults(18-64 years)	232		
Adults(65-84 years)	37		
Adults(85 years and over)	0		
Age Continuous Units: Years arithmetic mean standard deviation	- -		
Sex: Female, Male Units: Subjects			
Female	210		
Male	59		
Race/Ethnicity, Customized Units: Subjects			
White	254		
Black or African American	0		
Asian	8		
American Indian or Alaska Native	2		
Native Hawaiian or Other Pacific Islander	0		
Other	5		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Subjects received 4 matching PF-06650833 modified release (MR) placebo tablets once daily (QD) and 1 matching tofacitinib placebo tablet twice a day (BID) in 12 weeks treatment period.	
Reporting group title	Tofa 10 mg
Reporting group description:	
Subjects received 4 matching PF-06650833 MR placebo tablets QD and 1 tofacitinib 5 mg tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 20 mg
Reporting group description:	
Subjects received 1 MR tablet of PF-06650833 20 mg and 3 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 60 mg
Reporting group description:	
Subjects received 3 MR tablets of PF-06650833 20 mg and 1 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 200 mg
Reporting group description:	
Subjects received 2 MR tablets of PF-06650833 100 mg and 2 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	
Reporting group title	PF-06650833 400 mg
Reporting group description:	
Subjects received 4 MR tablets of PF-06650833 100 mg QD and 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.	

Primary: Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12

End point title	Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12[1]
End point description:	
The SDAI is a continuous composite measure derived from components of the American College of Rheumatology (ACR) Core Dataset.The SDAI was calculated using the following formula: SDAI = Tender / Painful Joint Count(TJC) (using 28 joints) + Swollen Joint Count (SJC) (using 28 joints) + Patient Global Assessment of Arthritis (PtGA) (0–10 cm scale) + Physician's Global Assessment of Arthritis (PhGA) (0–10 cm scale) + high sensitivity C-reactive protein (hsCRP) (mg/dL).	
End point type	Primary
End point timeframe:	
Baseline and Week 12	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	34	30	45	44
Units: units on a scale				
arithmetic mean (confidence interval 95%)				

Week 12	-13.87 (-17.70 to -10.02)	-21.71 (-26.14 to -17.20)	-22.83 (-26.57 to -19.20)	-24.77 (-28.54 to -21.08)

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	45			
Units: units on a scale				
arithmetic mean (confidence interval 95%)				
Week 12	-25.16 (-28.85 to -21.39)			

Statistical analyses

Statistical analysis title	Statistical Comparison in SDAI at Week 12
Statistical analysis description:	
Bayesian analysis of covariance (ANCOVA) modeling framework was used with baseline SDAI score as a covariate. The Confidence Interval was Credible Interval in this analysis.	
Comparison groups	Placebo v PF-06650833 20 mg
Number of subjects included in analysis	64
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.005
Method	ANCOVA
Parameter estimate	Mean difference (net)
Point estimate	-7.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	-13.73
upper limit	-1.97

Statistical analysis title	Statistical Comparison in SDAI at Week 12
Statistical analysis description:	
Bayesian analysis of covariance (ANCOVA) modeling framework was used with baseline SDAI score as a covariate. The Confidence Interval was Credible Interval in this analysis.	
Comparison groups	Placebo v PF-06650833 60 mg
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (net)
Point estimate	-8.96
Confidence interval	

level	95 %
sides	2-sided
lower limit	-14.37
upper limit	-3.66

Statistical analysis title	Statistical Comparison in SDAI at Week 12

Statistical analysis description:

Bayesian analysis of covariance (ANCOVA) modeling framework was used with baseline SDAI score as a covariate. The Confidence Interval was Credible Interval in this analysis.

Comparison groups	Placebo v PF-06650833 200 mg
Number of subjects included in analysis	78
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (net)
Point estimate	-10.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.36
upper limit	-5.63

Statistical analysis title	Statistical Comparison in SDAI at Week 12

Statistical analysis description:

Bayesian analysis of covariance (ANCOVA) modeling framework was used with baseline SDAI score as a covariate. The Confidence Interval was Credible Interval in this analysis.

Comparison groups	Placebo v PF-06650833 400 mg
Number of subjects included in analysis	79
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	ANCOVA
Parameter estimate	Mean difference (net)
Point estimate	-11.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.62
upper limit	-5.92

Secondary: Change From Baseline in SDAI at Weeks 4 and 8

End point title	Change From Baseline in SDAI at Weeks 4 and 8[2]

End point description:

The SDAI is a continuous composite measure derived from components of the American College of Rheumatology (ACR) Core Dataset.The SDAI was calculated using the following formula: SDAI = TJC (using 28 joints) + SJC (using 28 joints) + PtGA (0–10 cm scale) + PhGA (0–10 cm scale) + hsCRP (mg/dL).

End point type	Secondary

End point timeframe:

Baseline, Weeks 4 and 8

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[3]	39[4]	50[5]	50[6]
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-10.78 (-15.07 to -6.49)	-12.39 (-14.68 to -10.10)	-14.29 (-16.87 to -11.71)	-13.56 (-17.25 to -9.86)
Week 8	-17.07 (-22.58 to -11.55)	-16.62 (-20.71 to -12.53)	-18.85 (-22.03 to -15.67)	-19.95 (-24.81 to -15.08)

Notes:

[3] - Number of Subjects Analyzed at Weeks 4 and 8: 37, 34

[4] - Number of Subjects Analyzed at Weeks 4 and 8: 37, 34

[5] - Number of Subjects Analyzed at Weeks 4 and 8: 49, 46

[6] - Number of Subjects Analyzed at Weeks 4 and 8: 47, 41

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[7]			
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-12.30 (-15.46 to -9.14)			
Week 8	-21.15 (-25.50 to -16.79)			

Notes:

[7] - Number of Subjects Analyzed at Weeks 4 and 8: 47, 45

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at Weeks 4, 8 and 12

End point title	Percentage of Subjects With SDAI Low Disease Activity Score (LDAS) (SDAI <=11) at Weeks 4, 8 and 12[8]

End point description:

The SDAI is a continuous composite measure derived from components of the American College of Rheumatology (ACR) Core Dataset.The SDAI was calculated using the following formula: SDAI = TJC (using 28 joints) + SJC (using 28 joints) + PtGA (0–10 cm scale) + PhGA (0–10 cm scale) + hsCRP (mg/dL). The criterion of SDAI LDAS was SDAI<=11.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[9]	39[10]	50[11]	50[12]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	8.1 (0.0 to 16.9)	7.9 (0.0 to 16.5)	12.2 (3.1 to 21.4)	10.6 (1.8 to 19.5)
Week 8	14.7 (2.8 to 26.6)	20.0 (6.7 to 33.3)	17.4 (6.4 to 28.3)	29.3 (15.3 to 43.2)
Week 12	26.5 (11.6 to 41.3)	41.9 (24.6 to 59.3)	28.9 (15.6 to 42.1)	38.6 (24.2 to 53.0)

Notes:

[9] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[10] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[11] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[12] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[13]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	8.5 (0.5 to 16.5)			
Week 8	33.3 (19.6 to 47.1)			
Week 12	42.2 (27.8 to 56.7)			

Notes:

[13] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with SDAI Remission (SDAI <=3.3) at Weeks 4, 8 and 12

End point title	Percentage of Subjects with SDAI Remission (SDAI <=3.3) at Weeks 4, 8 and 12[14]

End point description:

The SDAI is a continuous composite measure derived from components of the American College of Rheumatology (ACR) Core Dataset.The SDAI was calculated using the following formula: SDAI = TJC (using 28 joints) + SJC (using 28 joints) + PtGA (0–10 cm scale) + PhGA (0–10 cm scale) + hsCRP (mg/dL). The criterion of SDAI remission was SDAI<=3.3.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[15]	39[16]	50[17]	50[18]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	0 (0.0 to 0.0)	2.6 (0.0 to 7.7)	2.0 (0.0 to 6.0)	0 (0.0 to 0.0)
Week 8	0 (0.0 to 0.0)	8.6 (0.0 to 17.8)	0 (0.0 to 0.0)	7.3 (0.0 to 15.3)
Week 12	2.9 (0.0 to 8.6)	3.2 (0.0 to 9.4)	2.2 (0.0 to 6.5)	6.8 (0.0 to 14.3)

Notes:

[15] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[16] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[17] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[18] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[19]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	2.1 (0.0 to 6.3)			
Week 8	2.2 (0.0 to 6.5)			
Week 12	8.9 (0.6 to 17.2)			

Notes:

[19] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Disease Activity Score-28 (4 Components Based on Erythrocyte Sedimentation Rate) (DAS28-4 [ESR]) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12

End point title	Percentage of Subjects with Disease Activity Score-28 (4 Components Based on Erythrocyte Sedimentation Rate) (DAS28-4 [ESR]) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12[20]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (ESR) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, ESR and PtGA. DAS28-4 (ESR) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.70 ln(ESR [mm/first hour] + 0.014 (PtGA [mm]). Higher score indicated more disease activity. The criterion of DAS28-4 LDAS was DAS28<3.2.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[21]	39[22]	50[23]	50[24]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	2.9 (0.0 to 8.4)	8.1 (0.0 to 16.9)	6.4 (0.0 to 13.4)	8.3 (0.5 to 16.2)
Week 8	8.6 (0.0 to 17.8)	17.1 (4.7 to 29.6)	13.6 (3.5 to 23.8)	13.3 (3.4 to 23.3)
Week 12	17.6 (4.8 to 30.5)	20.0 (5.7 to 34.3)	24.4 (11.9 to 37.0)	22.2 (10.1 to 34.4)

Notes:

[21] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 35, 34, 34.

[22] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 30.

[23] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 44, 45.

[24] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 45, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[25]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	4.3 (0.0 to 10.0)			
Week 8	12.8 (3.2 to 22.3)			
Week 12	17.8 (6.6 to 28.9)			

Notes:

[25] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With DAS28-3 (ESR) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12

End point title	Percentage of Subjects With DAS28-3 (ESR) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12[26]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-3 (ESR) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed and ESR. DAS28-3 (ESR) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.70 ln(ESR [mg/L]*1.08 + 0.16. Higher score indicated more disease activity. The criterion of DAS28-3 LDAS was DAS28<3.2.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[27]	39[28]	50[29]	50[30]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	5.7 (0.0 to 13.4)	8.1 (0.0 to 16.9)	10.6 (1.8 to 19.5)	8.3 (0.5 to 16.2)
Week 8	8.6 (0.0 to 17.8)	20.0 (6.7 to 33.3)	15.9 (5.1 to 26.7)	8.9 (0.6 to 17.2)
Week 12	20.6 (7.0 to 34.2)	20.0 (5.7 to 34.3)	22.2 (10.1 to 34.4)	22.2 (10.1 to 34.4)

Notes:

[27] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 35, 35, 34.

[28] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 30.

[29] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 44, 45.

[30] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 45, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[31]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	4.3 (0.0 to 10.0)			
Week 8	14.9 (4.7 to 25.1)			
Week 12	15.6 (5.0 to 26.1)			

Notes:

[31] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects with Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12

End point title	Percentage of Subjects with Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12[32]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, hs-CRP and PtGA. DAS28-4 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] +1) + 0.014 (PtGA [mm]) + 0.96. Higher score indicated more disease activity. The

possible lowest score is 0.96. The possible highest score is difficult to be determined, due to indeterminable nature of hs-CRP level; assuming hs-CRP level is 0 to 500 mg/L, the possible highest score would be 6.8 (when hs-CRP is 0) to 9.04 (when hs-CRP is 500 mg/L). The criterion of DAS28-4 LDAS was DAS28<3.2.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[33]	39[34]	50[35]	50[36]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	8.1 (0.0 to 16.9)	13.2 (2.4 to 23.9)	16.3 (6.0 to 26.7)	12.8 (3.2 to 22.3)
Week 8	11.8 (0.9 to 22.6)	20.0 (6.7 to 33.3)	19.6 (8.1 to 31.0)	26.8 (13.3 to 40.4)
Week 12	20.6 (7.0 to 34.2)	38.7 (21.6 to 55.9)	35.6 (21.6 to 49.5)	40.9 (26.4 to 55.4)

Notes:

[33] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[34] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[35] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[36] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[37]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	8.5 (0.5 to 16.5)			
Week 8	33.3 (19.6 to 47.1)			
Week 12	42.2 (27.8 to 56.7)			

Notes:

[37] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With DAS28-3 (CRP) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12

End point title	Percentage of Subjects With DAS28-3 (CRP) LDAS (DAS28 <3.2) at Weeks 4, 8, and 12[38]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to

each component. The components of the DAS28-3 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed and hs-CRP. DAS28-3 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] +1)*1.10+ 1.15. Higher score indicated more disease activity. The possible lowest score is 0.96. The possible highest score is difficult to be determined, due to indeterminable nature of hs-CRP level; assuming hs-CRP level is 0 to 500 mg/L, the possible highest score would be 6.8 (when hs-CRP is 0) to 9.04 (when hs-CRP is 500 mg/L). The criterion of DAS28-3 LDAS was DAS28<3.2.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[39]	39[40]	50[41]	50[42]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	8.1 (0.0 to 16.9)	10.5 (0.8 to 20.3)	16.3 (6.0 to 26.7)	17.0 (6.3 to 27.8)
Week 8	20.6 (7.0 to 34.2)	22.9 (8.9 to 36.8)	19.6 (8.1 to 31.0)	34.1 (19.6 to 48.7)
Week 12	23.5 (9.3 to 37.8)	41.9 (24.6 to 59.3)	40.0 (25.7 to 54.3)	47.7 (33.0 to 62.5)

Notes:

[39] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[40] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[41] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[42] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[43]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	10.6 (1.8 to 19.5)			
Week 8	37.8 (23.6 to 51.9)			
Week 12	42.2 (27.8 to 56.7)			

Notes:

[43] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With DAS28-4 (ESR) Remission (DAS28 <2.6) at Weeks 4, 8 and 12

End point title	Percentage of Subjects With DAS28-4 (ESR) Remission (DAS28 <2.6) at Weeks 4, 8 and 12[44]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (ESR) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, ESR and PtGA. DAS28-4 (ESR) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.70 ln(ESR [mg/L] + 0.014 (PtGA [mm]). Higher score indicated more disease activity. The criterion of DAS28-4 remission was DAS28<2.6.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[45]	39[46]	50[47]	50[48]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	0 (0.0 to 0.0)	5.4 (0.0 to 12.7)	2.1 (0.0 to 6.3)	8.3 (0.5 to 16.2)
Week 8	5.7 (0.0 to 13.4)	11.4 (0.9 to 22.0)	9.1 (0.6 to 17.6)	6.7 (0.0 to 14.0)
Week 12	5.9 (0.0 to 13.8)	16.7 (3.3 to 30.0)	13.3 (3.4 to 23.3)	8.9 (0.6 to 17.2)

Notes:

[45] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 35, 35, 34.

[46] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 30.

[47] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 44, 45.

[48] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 45, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[49]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	2.1 (0.0 to 6.3)			
Week 8	10.6 (1.8 to 19.5)			
Week 12	11.1 (1.9 to 20.3)			

Notes:

[49] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With DAS28-3 (ESR) Remission (DAS28 <2.6) at Weeks 4, 8 and 12

End point title	Percentage of Subjects With DAS28-3 (ESR) Remission (DAS28 <2.6) at Weeks 4, 8 and 12[50]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-3 (ESR) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed and ESR. DAS28-3 (ESR) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.70 ln(ESR [mg/L]*1.08 + 0.16. Higher score indicated more disease activity. The criterion of DAS28-3 remission was DAS28<2.6.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[51]	39[52]	50[53]	50[54]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	0 (0.0 to 0.0)	2.7 (0.0 to 7.9)	2.1 (0.0 to 6.3)	6.3 (0.0 to 13.1)
Week 8	2.9 (0.0 to 8.4)	8.6 (0.0 to 17.8)	9.1 (0.6 to 17.6)	6.7 (0.0 to 14.0)
Week 12	8.8 (0.0 to 18.4)	10.0 (0.0 to 20.7)	13.3 (3.4 to 23.3)	11.1 (1.9 to 20.3)

Notes:

[51] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 35, 35, 34.

[52] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 30.

[53] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 44, 45.

[54] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 45, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[55]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	2.1 (0.0 to 6.3)			
Week 8	8.5 (0.5 to 16.5)			
Week 12	8.9 (0.6 to 17.2)			

Notes:

[55] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With DAS28-4 (CRP) Remission (DAS28 <2.6) at Weeks 4, 8 and 12

End point title	Percentage of Subjects With DAS28-4 (CRP) Remission (DAS28 <2.6) at Weeks 4, 8 and 12[56]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, hs-CRP and PtGA. DAS28-4 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] +1) + 0.014 (PtGA [mm]) + 0.96. Higher score indicated more disease activity. The possible lowest score is 0.96. The possible highest score is difficult to be determined, due to indeterminable nature of hs-CRP level; assuming hs-CRP level is 0 to 500 mg/L, the possible highest score would be 6.8 (when hs-CRP is 0) to 9.04 (when hs-CRP is 500 mg/L). The criterion of DAS28-4 remission was DAS28<2.6.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[57]	39[58]	50[59]	50[60]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	2.7 (0.0 to 7.9)	5.3 (0.0 to 12.4)	8.2 (0.5 to 15.8)	10.6 (1.8 to 19.5)
Week 8	8.8 (0.0 to 18.4)	17.1 (4.7 to 29.6)	10.9 (1.9 to 19.9)	22.0 (9.3 to 34.6)
Week 12	14.7 (2.8 to 26.6)	22.6 (7.9 to 37.3)	17.8 (6.6 to 28.9)	25.0 (12.2 to 37.8)

Notes:

[57] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[58] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[59] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[60] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[61]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	6.4 (0.0 to 13.4)			
Week 8	13.3 (3.4 to 23.3)			
Week 12	24.4 (11.9 to 37.0)			

Notes:

[61] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With DAS28-3 (CRP) Remission (DAS28 <2.6) at

Weeks 4, 8 and 12

End point title	Percentage of Subjects With DAS28-3 (CRP) Remission (DAS28 <2.6) at Weeks 4, 8 and 12[62]

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-3 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed and hs-CRP. DAS28-3 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] +1)*1.10+ 1.15. Higher score indicated more disease activity. The possible lowest score is 1.15. The possible highest score is difficult to be determined, due to indeterminable nature of hs-CRP level. The criterion of DAS28-3 remission was DAS28<2.6.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[63]	39[64]	50[65]	50[66]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	5.4 (0.0 to 12.7)	5.3 (0.0 to 12.4)	10.2 (1.7 to 18.7)	8.5 (0.5 to 16.5)
Week 8	8.8 (0.0 to 18.4)	14.3 (2.7 to 25.9)	10.9 (1.9 to 19.9)	22.0 (9.3 to 34.6)
Week 12	11.8 (0.9 to 22.6)	25.8 (10.4 to 41.2)	22.2 (10.1 to 34.4)	22.7 (10.3 to 35.1)

Notes:

[63] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[64] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[65] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[66] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[67]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	4.3 (0.0 to 10.0)			
Week 8	13.3 (3.4 to 23.3)			
Week 12	22.2 (10.1 to 34.4)			

Notes:

[67] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in DAS28-4 (ESR) at Weeks 4, 8 and 12

End point title	Change From Baseline in DAS28-4 (ESR) at Weeks 4, 8 and

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (ESR) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, ESR and PtGA. DAS28-4 (ESR) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.70 ln(ESR [mm/first hour] + 0.014 (PtGA [mm]). Higher score indicated more disease activity.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[68] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[69]	39[70]	50[71]	50[72]
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-0.80 (-1.13 to -0.47)	-1.15 (-1.47 to -0.82)	-1.35 (-1.64 to -1.07)	-1.14 (-1.42 to -0.86)
Week 8	-1.38 (-1.80 to -0.97)	-1.59 (-2.01 to -1.17)	-1.92 (-2.29 to -1.56)	-1.77 (-2.14 to -1.41)
Week 12	-1.55 (-1.97 to -1.13)	-1.85 (-2.28 to -1.41)	-2.37 (-2.74 to -2.01)	-2.23 (-2.60 to -1.86)

Notes:

[69] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 35, 35, 34.

[70] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 30.

[71] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 44, 45.

[72] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 45, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[73]			
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-1.13 (-1.42 to -0.84)			
Week 8	-2.01 (-2.37 to -1.64)			
Week 12	-2.36 (-2.73 to -1.99)			

Notes:

[73] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in DAS28-3 (ESR) at Weeks 4, 8 and 12

End point title	Change From Baseline in DAS28-3 (ESR) at Weeks 4, 8 and

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-3 (ESR) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed and ESR. DAS28-3 (ESR) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.70 ln(ESR [mm/first hour]*1.08 + 0.16. Higher score indicated more disease activity.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[74] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[75]	39[76]	50[77]	50[78]
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-0.69 (-1.01 to -0.38)	-1.08 (-1.39 to -0.77)	-1.25 (-1.52 to -0.97)	-1.08 (-1.35 to -0.80)
Week 8	-1.14 (-1.54 to -0.75)	-1.52 (-1.92 to -1.12)	-1.80 (-2.15 to -1.45)	-1.62 (-1.97 to -1.27)
Week 12	-1.31 (-1.71 to -0.92)	-1.69 (-2.09 to -1.28)	-2.26 (-2.60 to -1.91)	-2.05 (-2.40 to -1.71)

Notes:

[75] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 35, 35, 34.

[76] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 30.

[77] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 44, 45.

[78] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 45, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[79]			
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-1.02 (-1.29 to -0.74)			
Week 8	-1.79 (-2.14 to -1.44)			
Week 12	-2.04 (-2.38 to -1.69)			

Notes:

[79] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in DAS28-4 (CRP) at Weeks 4, 8 and 12

End point title	Change From Baseline in DAS28-4 (CRP) at Weeks 4, 8 and

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, hs-CRP and PGtA. DAS28-4 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] +1) + 0.014 (PGtA [mm]) + 0.96. Higher score indicated more disease activity. The possible lowest score is 0.96. The possible highest score is difficult to be determined, due to indeterminable nature of hs-CRP level; assuming hs-CRP level is 0 to 500 mg/L, the possible highest score would be 6.8 (when hs-CRP is 0) to 9.04 (when hs-CRP is 500 mg/L).

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[80] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[81]	39[82]	50[83]	50[84]
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-0.72 (-1.02 to -0.42)	-0.99 (-1.29 to -0.69)	-1.21 (-1.47 to -0.94)	-1.08 (-1.34 to -0.81)
Week 8	-1.20 (-1.58 to -0.83)	-1.31 (-1.68 to -0.94)	-1.59 (-1.92 to -1.27)	-1.65 (-1.98 to -1.32)
Week 12	-1.38 (-1.78 to -0.97)	-1.67 (-2.08 to -1.26)	-1.94 (-2.29 to -1.59)	-2.00 (-2.36 to -1.65)

Notes:

[81] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[82] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[83] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[84] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[85]			
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-0.99 (-1.25 to -0.72)			
Week 8	-1.73 (-2.06 to -1.40)			
Week 12	-2.12 (-2.47 to -1.77)			

Notes:

[85] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in DAS28-3 (CRP) at Weeks 4, 8 and 12

End point title	Change From Baseline in DAS28-3 (CRP) at Weeks 4, 8 and

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-3 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed and hs-CRP. DAS28-3 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] +1)*1.10+ 1.15. Higher score indicated more disease activity. The possible lowest score is 0.96. The possible highest score is difficult to be determined, due to indeterminable nature of hs-CRP level; assuming hs-CRP level is 0 to 500 mg/L, the possible highest score would be 6.8 (when hs-CRP is 0) to 9.04 (when hs-CRP is 500 mg/L).

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[87]	39[88]	50[89]	50[90]
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-0.61 (-0.90 to -0.32)	-0.93 (-1.22 to -0.64)	-1.09 (-1.35 to -0.84)	-1.01 (-1.27 to -0.76)
Week 8	-0.97 (-1.32 to -0.61)	-1.24 (-1.60 to -0.89)	-1.46 (-1.76 to -1.15)	-1.52 (-1.83 to -1.20)
Week 12	-1.14 (-1.52 to -0.77)	-1.53 (-1.91 to -1.15)	-1.82 (-2.14 to -1.50)	-1.83 (-2.51 to -1.50)

Notes:

[87] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 34, 34.

[88] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 38, 35, 31.

[89] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 49, 46, 45.

[90] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[91]			
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-0.88 (-1.14 to -0.62)			
Week 8	-1.52 (-1.83 to -1.21)			
Week 12	-1.82 (-2.51 to -1.50)			

Notes:

[91] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Weeks 4, 8 and 12

End point title	Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Weeks 4, 8 and 12[92]

End point description:

ACR20 was calculated as a 20% improvement in TJC and SJC and 20% improvement in 3 of the 5 remaining ACR-core set measures: PtGA and PhGA, pain, disability, and an acute-phase reactant which for this study was CRP or ESR.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[92] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[93]	39[94]	50[95]	50[96]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	30.8 (16.3 to 45.3)	35.9 (20.8 to 51.0)	42.0 (28.3 to 55.7)	40.0 (26.4 to 53.6)
Week 8	46.2 (30.5 to 61.8)	51.3 (35.6 to 67.0)	58.0 (44.3 to 71.7)	52.0 (38.2 to 65.8)
Week 12	51.3 (35.6 to 67.0)	48.7 (33.0 to 64.4)	66.0 (52.9 to 79.1)	62.0 (48.5 to 75.5)

Notes:

[93] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 39, 39, 39.

[94] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 39, 39, 39.

[95] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 50, 50, 50.

[96] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 50, 50, 50.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[97]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	37.5 (23.8 to 51.2)			
Week 8	64.6 (51.1 to 78.1)			

Week 12	70.8 (58.0 to 83.7)			

Notes:

[97] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 48, 48.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Weeks 4, 8 and 12

End point title	Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Weeks 4, 8 and 12[98]

End point description:

ACR50 was calculated as a 50% improvement in TJC and SJC and 50% improvement in 3 of the 5 remaining ACR-core set measures: PtGA and PhGA, pain, disability, and an acute-phase reactant which for this study was CRP or ESR.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[98] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[99]	39[100]	50[101]	50[102]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	2.6 (0.0 to 7.5)	10.3 (0.7 to 19.8)	6.0 (0.0 to 12.6)	6.0 (0.0 to 12.6)
Week 8	12.8 (2.3 to 23.3)	23.1 (9.9 to 36.3)	14.0 (4.4 to 23.6)	22.0 (10.5 to 33.5)
Week 12	20.5 (7.8 to 33.2)	25.6 (11.9 to 39.3)	22.0 (10.5 to 33.5)	40.0 (26.4 to 53.6)

Notes:

[99] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 39, 39, 39.

[100] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 39, 39, 39.

[101] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 50, 50, 50.

[102] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 50, 50, 50.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[103]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	8.3 (0.5 to 16.2)			
Week 8	35.4 (21.9 to 48.9)			

Week 12	43.8 (29.7 to 57.8)			

Notes:

[103] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 48, 48.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Weeks 4, 8 and 12

End point title	Percentage of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Weeks 4, 8 and 12[104]

End point description:

ACR70 was calculated as a 70% improvement in TJC and SJC and 70% improvement in 3 of the 5 remaining ACR-core set measures: PtGA and PhGA, pain, disability, and an acute-phase reactant which for this study was CRP or ESR.

End point type	Secondary

End point timeframe:

Weeks 4, 8 and 12

Notes:

[104] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[105]	39[106]	50[107]	50[108]
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	0.0 (0.0 to 0.0)	5.1 (0.0 to 12.1)	0.0 (0.0 to 0.0)	0.0 (0.0 to 0.0)
Week 8	2.6 (0.0 to 7.5)	10.3 (0.7 to 19.8)	0.0 (0.0 to 0.0)	10.0 (1.7 to 18.3)
Week 12	5.1 (0.0 to 12.1)	7.7 (0.0 to 16.1)	6.0 (0.0 to 12.6)	14.0 (4.4 to 23.6)

Notes:

[105] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 39, 39, 39.

[106] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 39, 39, 39.

[107] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 50, 50, 50.

[108] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 50, 50, 50.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[109]			
Units: percentage of subjects				
number (confidence interval 95%)				
Week 4	4.2 (0.0 to 9.8)			
Week 8	6.3 (0.0 to 13.1)			

Week 12	10.4 (1.8 to 19.1)			

Notes:

[109] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 48, 48, 48.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Tender/Painful and Swollen Joint Counts at Weeks 4, 8 and 12

End point title	Change From Baseline in the Tender/Painful and Swollen Joint Counts at Weeks 4, 8 and 12[110]

End point description:

The TJC (28) included the following joints: shoulders, elbows, wrists, metacarpophalangeal (MCP) joints, proximal interphalangeal (PIP) joints, and knees. This count was calculated from the TJC (68) assessed. The SJC (28) included the same joints as TJC (28), and was calculated from the SJC 66 assessed for swelling.Sixty eight (68) joints were assessed by a blinded joint assessor to determine the number of joints that were considered tender or painful. The 68 joints assessed were: temporomandibular, sternoclavicular, acromioclavicular; shoulder, elbow, wrist, metacarpophalangeals, thumb interphalangeal, proximal interphalangeals, and distal interphalangeals; lower extremity including hip, knee, ankle, tarsus, metatarsophalangeals, great toe interphalangeal, proximal and distal interphalangeals combined. Sixty-six (66) joints were assessed for swelling, the same as those listed for TJC, excluding the right and left hip joints.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[110] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[111]	39[112]	50[113]	50[114]
Units: joints				
arithmetic mean (standard deviation)				
SJC (28) at Week 4	-4.4 (± 6.01)	-4.8 (± 3.64)	-4.4 (± 3.76)	-5.0 (± 4.87)
SJC (28) at Week 8	-6.1 (± 6.75)	-6.0 (± 4.70)	-6.1 (± 4.80)	-7.0 (± 5.31)
SJC (28) at Week 12	-6.3 (± 5.61)	-6.8 (± 5.21)	-6.6 (± 5.38)	-8.1 (± 5.73)
TJC (28) at Week 4	-4.0 (± 5.99)	-4.9 (± 5.01)	-5.5 (± 5.12)	-4.8 (± 6.14)
TJC (28) at Week 8	-5.9 (± 7.16)	-6.9 (± 6.18)	-7.0 (± 5.83)	-7.5 (± 7.13)
TJC (28) at Week 12	-7.5 (± 6.39)	-8.6 (± 6.36)	-9.5 (± 6.14)	-9.9 (± 7.24)
SJC (66) at Week 4	-6.2 (± 10.82)	-6.5 (± 5.07)	-6.3 (± 5.27)	-8.6 (± 9.00)
SJC (66) at Week 8	-9.0 (± 10.87)	-8.2 (± 7.03)	-8.5 (± 6.74)	-11.0 (± 8.81)
SJC (66) at Week 12	-9.4 (± 9.92)	-9.6 (± 7.76)	-8.8 (± 7.11)	-12.5 (± 9.00)
TJC (68) at Week 4	-4.9 (± 11.28)	-8.7 (± 8.96)	-9.1 (± 8.45)	-9.1 (± 12.22)
TJC (68) at Week 8	-10.0 (± 13.41)	-10.9 (± 10.48)	-11.3 (± 9.46)	-14.0 (± 14.61)
TJC (68) at Week 12	-11.5 (± 12.24)	-13.5 (± 11.44)	-15.5 (± 11.30)	-18.1 (± 15.00)

Notes:

[111] - Number of Subjects Analyzed at Weeks 4, 8 and 12: 37, 35, 34.

[112] - Number of Subjects Analyzed at Weeks 4, 8 and 12:38, 35, 31.

[113] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 45.

[114] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[115]			
Units: joints				
arithmetic mean (standard deviation)				
SJC (28) at Week 4	-3.8 (± 4.25)			
SJC (28) at Week 8	-6.8 (± 5.75)			
SJC (28) at Week 12	-8.2 (± 6.01)			
TJC (28) at Week 4	-4.4 (± 5.36)			
TJC (28) at Week 8	-7.8 (± 6.72)			
TJC (28) at Week 12	-9.6 (± 6.65)			
SJC (66) at Week 4	-6.2 (± 8.00)			
SJC (66) at Week 8	-10.0 (± 9.92)			
SJC (66) at Week 12	-11.6 (± 10.19)			
TJC (68) at Week 4	-7.8 (± 9.60)			
TJC (68) at Week 8	-12.2 (± 11.40)			
TJC (68) at Week 12	-14.8 (± 11.98)			

Notes:

[115] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP) at Weeks 4, 8 and 12

End point title	Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP) at Weeks 4, 8 and 12[116]

End point description:

Serum samples were analyzed to determine the level of hs-CRP, which was an acute-phase reactant.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[116] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[117]	39[118]	50[119]	50[120]
Units: mg/dL				
least squares mean (confidence interval 95%)				
Week 4	0.22 (-0.17 to 0.60)	-0.15 (-0.53 to 0.23)	-0.66 (-1.00 to -0.32)	-0.66 (-1.00 to -0.32)
Week 8	0.12 (-0.35 to 0.59)	0.07 (-0.39 to 0.53)	-0.91 (-1.31 to -0.50)	-0.62 (-1.04 to -0.20)
Week 12	-0.07 (-0.54 to 0.39)	-0.23 (-0.71 to 0.25)	-0.74 (-1.14 to -0.34)	-0.68 (-1.09 to -0.27)

Notes:

[117] - Number of Subjects Analyzed at Weeks 4, 8 and 12:37, 34, 34.

[118] - Number of Subjects Analyzed at Weeks 4, 8 and 12:38, 35, 31.

[119] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 46.

[120] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 41, 44.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[121]			
Units: mg/dL				
least squares mean (confidence interval 95%)				
Week 4	-0.65 (-1.00 to -0.31)			
Week 8	-0.61 (-1.02 to -0.20)			
Week 12	-0.64 (-1.04 to -0.23)			

Notes:

[121] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 45, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Physician’s Global Assessment of Arthritis (PhGA) at Weeks 4, 8, and 12

End point title	Change From Baseline in the Physician’s Global Assessment of Arthritis (PhGA) at Weeks 4, 8, and 12[122]

End point description:

The investigator assessed how the participant’s overall arthritis appeared at the time of the visit. This was an evaluation based on the participant’s disease symptoms, functional capacity and physical examination, and was independent of the participant’s reported assessments of PtGA (patient’s global assessment of arthritis). The investigator’s response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled “None” and the 100 mm end labeled “Extreme”.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[122] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[123]	39[124]	50[125]	50[126]
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-14.30 (-20.06 to -8.54)	-18.54 (-24.31 to -12.78)	-22.51 (-27.53 to -17.49)	-18.34 (-23.34 to -13.33)
Week 8	-25.86 (-32.11 to -19.62)	-26.80 (-33.12 to -20.48)	-27.76 (-33.21 to -22.31)	-27.86 (-33.31 to -22.42)
Week 12	-28.16 (-34.59 to -21.74)	-30.28 (-36.98 to -23.58)	-33.05 (-38.61 to -27.49)	-34.27 (-39.86 to -28.68)

Notes:

[123] - Number of Subjects Analyzed at Weeks 4, 8 and 12:37, 35, 34.

[124] - Number of Subjects Analyzed at Weeks 4, 8 and 12:37, 34, 30.

[125] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 46.

[126] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[127]			
Units: units on a scale				
least squares mean (confidence interval 95%)				
Week 4	-18.06 (-23.20 to -12.92)			
Week 8	-29.97 (-35.42 to -24.52)			
Week 12	-36.34 (-41.95 to -30.73)			

Notes:

[127] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment-Related TEAEs

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment-Related TEAEs

End point description:

AE was defined as any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of the causal relationship to study treatment. Treatment-emergent AEs (TEAEs) were defined as AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were defined as any untoward medical occurrence at any dose that resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Causality to study treatment was determined by the investigator.

End point type	Secondary

End point timeframe:

Baseline up to primary completion date (PCD) (about 21 months)

End point values	Placebo	Tofa 10 mg	PF-06650833 20 mg	PF-06650833 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39	43	39	50
Units: subjects				
TEAEs (all causality)	17	17	20	27
TEAEs (treatment-related)	8	6	12	8
SAEs (all causality)	1	1	1	1
SAEs (treatment-related)	0	0	1	0

End point values	PF-06650833 200 mg	PF-06650833 400 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	48		
Units: subjects				
TEAEs (all causality)	19	23		
TEAEs (treatment-related)	8	6		
SAEs (all causality)	1	3		
SAEs (treatment-related)	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

End point title	Number of Subjects With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

End point description:

Laboratory evaluation included hematology, clinical chemistry, and urinalysis. Each parameter was evaluated against commonly used and widely accepted criteria.

End point type	Secondary

End point timeframe:

Baseline up to PCD (about 21 months)

End point values	Placebo	Tofa 10 mg	PF-06650833 20 mg	PF-06650833 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	43	39	50
Units: subjects	30	32	30	36

End point values	PF-06650833 200 mg	PF-06650833 400 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	48		
Units: subjects	41	38		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Vital Signs Data Meeting Pre-sepcified Criteria

End point title	Number of Subjects With Vital Signs Data Meeting Pre-sepcified Criteria

End point description:

Vital signs tests included systolic blood pressure (SBP) and diastolic blood pressure (DBP) and pulse rate. Vital signs categorical summarization criteria were 1), SBP <90 mmHg or change from baseline (Chg) >=30 mmHg; DBP <50 mmHg or Chg >=20 mmHg. 2), pulse rate <40 bpm or >120 bpm.

End point type	Secondary

End point timeframe:

Baseline up to PCD (about 21 months)

End point values	Placebo	Tofa 10 mg	PF-06650833 20 mg	PF-06650833 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	43	39	50
Units: subjects				
Sitting Diastolic BP < 50 mmHg	1	0	0	0
Sitting Pulse Rate < 40 bpm	0	0	0	0
Sitting Pulse Rate > 120 bpm	0	0	0	0
Sitting Systolic BP < 90 mmHg	0	0	0	0
Increase: Sitting Systolic BP Chg >= 30 mmHg	0	0	1	1
Increase: Sitting Diastolic BP Chg >= 20 mmHg	1	2	3	0
Decrease: Sitting Systolic BP Chg >= 30 mmHg	2	3	0	2
Decrease: Sitting Diastolic BP Chg >= 20 mmHg	2	4	2	4

End point values	PF-06650833 200 mg	PF-06650833 400 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	48		

Units: subjects				
Sitting Diastolic BP < 50 mmHg	0	0		
Sitting Pulse Rate < 40 bpm	0	0		
Sitting Pulse Rate > 120 bpm	0	0		
Sitting Systolic BP < 90 mmHg	0	0		
Increase: Sitting Systolic BP Chg >= 30 mmHg	0	1		
Increase: Sitting Diastolic BP Chg >= 20 mmHg	1	2		
Decrease: Sitting Systolic BP Chg >= 30 mmHg	3	3		
Decrease: Sitting Diastolic BP Chg >= 20 mmHg	3	2		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Electrocardiogram (ECG) Data Meeting Pre-sepcified Criteria

End point title	Number of Subjects With Electrocardiogram (ECG) Data Meeting Pre-sepcified Criteria

End point description:

ECG evaluation included: PR interval, time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval), QT interval corrected for heart rate (QTc) using Fridericia's formula (QTcF interval), and QTc calculated using Bazett's correction factor (QTcB interval).

End point type	Secondary

End point timeframe:

Baseline up to PCD (about 21 months)

End point values	Placebo	Tofa 10 mg	PF-06650833 20 mg	PF-06650833 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	43	39	50
Units: subjects				
PR interval >=300 msec	0	0	0	0
QRS duration >=140 msec	0	0	0	0
QT interval >=500 msec	0	0	0	0
QTcB interval >=450 and <480 msec	5	4	5	4
QTcB interval >=480 and <500 msec	0	0	0	0
QTcB interval >=500 msec	0	0	0	0
QTcF interval >=450 and <480 msec	0	1	1	0
QTcF interval >=480 and <500 msec	0	0	0	0
QTcF interval >=500 msec	0	0	0	0
PR interval increase >=25/50%	0	0	0	0
QRS duration increase >=50%	0	0	0	0
QTcB interval increase >=30 and increase <60 msec	3	6	9	3
QTcB interval increase >=60 msec	0	0	0	0

QTcF interval increase >=30 and increase <60 msec	2	4	5	0
QTcF interval increase >=60 msec	0	0	0	0

End point values	PF-06650833 200 mg	PF-06650833 400 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	48		
Units: subjects				
PR interval >=300 msec	0	0		
QRS duration >=140 msec	0	0		
QT interval >=500 msec	0	0		
QTcB interval >=450 and <480 msec	5	13		
QTcB interval >=480 and <500 msec	0	0		
QTcB interval >=500 msec	0	0		
QTcF interval >=450 and <480 msec	1	4		
QTcF interval >=480 and <500 msec	0	0		
QTcF interval >=500 msec	0	0		
PR interval increase >=25/50%	1	0		
QRS duration increase >=50%	0	0		
QTcB interval increase >=30 and increase <60 msec	4	7		
QTcB interval increase >=60 msec	0	0		
QTcF interval increase >=30 and increase <60 msec	5	5		
QTcF interval increase >=60 msec	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Urinalysis Data Meeting Pre-specified Criteria

End point title	Number of Subjects With Urinalysis Data Meeting Pre-specified Criteria

End point description:

The urine sample was collected for central laboratory urinalysis and urine microscopy. The urinalysis included pH, protein, glucose, erythrocytes, leukocytes, ketones, nitrite, urobilinogen, urine bilirubin, urine hemoglobin, leukocyte esterase, granular casts, hyaline casts, bacteria, atypical, needle-like crystals urine, specific gravity, microscopy and urine albumin test.

End point type	Secondary

End point timeframe:

Baseline up to PCD (about 21 months)

End point values	Placebo	Tofa 10 mg	PF-06650833 20 mg	PF-06650833 60 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	43	39	50
Units: subjects				
Specific gravity <1.003	0	0	0	0
Specific gravity >1.030	3	0	0	3
pH <4.5	0	0	0	0
pH >8	0	0	0	0
Urine glucose >=1	0	0	4	2
Ketones >=1	3	0	1	2
Urine protein >=1	0	0	0	0
Urine hemoglobin >=1	7	5	6	5
Urobilinogen >=1	1	0	0	0
Urine bilirubin >=1	0	0	0	0
Nitrite >=1	3	5	3	1
Leukocyte esterase >=1	16	15	14	14
Urine erythrocytes(/HPF) >=20	1	2	3	1
Urine leukocytes (/HPF) >=20	4	3	2	2
Granular casts (/LPF) >1	1	1	0	0
Hyaline Casts (/LPF)	4	4	6	7
Bacteria >20	0	0	0	0
Atypical, needle-like crystals urine >=1	0	0	0	0

End point values	PF-06650833 200 mg	PF-06650833 400 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	49	48		
Units: subjects				
Specific gravity <1.003	0	0		
Specific gravity >1.030	2	2		
pH <4.5	0	0		
pH >8	0	0		
Urine glucose >=1	2	2		
Ketones >=1	1	1		
Urine protein >=1	1	0		
Urine hemoglobin >=1	12	6		
Urobilinogen >=1	0	1		
Urine bilirubin >=1	0	0		
Nitrite >=1	9	11		
Leukocyte esterase >=1	19	19		
Urine erythrocytes(/HPF) >=20	3	3		
Urine leukocytes (/HPF) >=20	7	7		
Granular casts (/LPF) >1	0	0		
Hyaline Casts (/LPF)	4	3		
Bacteria >20	0	0		
Atypical, needle-like crystals urine >=1	2	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Patient's Assessment of Arthritis Pain (PAAP) Visual Analogue Scale (VAS) at Weeks 4, 8, 12

End point title	Change From Baseline in the Patient's Assessment of Arthritis Pain (PAAP) Visual Analogue Scale (VAS) at Weeks 4, 8, 12[128]

End point description:

Patients assess the severity of their arthritis pain using a 100 mm VAS by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponds to the magnitude of their pain. This assessment was performed early in the clinic visit and before the subject had had extensive contact with site personnel and/or Investigator.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[128] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[129]	39[130]	50[131]	50[132]
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 4	-12.8 (± 18.85)	-11.5 (± 19.44)	-16.8 (± 20.19)	-9.5 (± 16.10)
Week 8	-22.4 (± 20.05)	-15.4 (± 21.32)	-22.2 (± 18.88)	-20.5 (± 23.70)
Week 12	-25.9 (± 26.39)	-21.4 (± 25.03)	-23.0 (± 21.46)	-25.7 (± 24.02)

Notes:

[129] - Number of Subjects Analyzed at Weeks 4, 8 and 12:37, 35, 34.

[130] - Number of Subjects Analyzed at Weeks 4, 8 and 12:38, 35, 31.

[131] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 46.

[132] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[133]			
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 4	-11.3 (± 21.22)			

Week 8	-23.5 (± 20.42)			
Week 12	-31.8 (± 23.70)			

Notes:

[133] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Patient Global Assessment of Arthritis (PtGA) VAS at Weeks 4, 8, 12

End point title	Change From Baseline in the Patient Global Assessment of Arthritis (PtGA) VAS at Weeks 4, 8, 12[134]

End point description:

Patients answer the following question: "Considering all the ways your arthritis affects you, how are you feeling today?" The patient's response is recorded using a 100 mm VAS. This assessment was performed early in the clinic visit and before the subject had had extensive contact with site personnel and/or Investigator. The higher score indicated more severe disease.

End point type	Secondary

End point timeframe:

Baseline, Weeks 4, 8 and 12

Notes:

[134] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[135]	39[136]	49[137]	50[138]
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 4	-12.0 (± 21.55)	-10.0 (± 16.68)	-14.9 (± 20.52)	-10.7 (± 19.11)
Week 8	-24.9 (± 21.25)	-13.1 (± 23.47)	-19.6 (± 19.60)	-22.2 (± 27.34)
Week 12	-25.9 (± 25.03)	-20.0 (± 23.12)	-19.7 (± 25.71)	-26.5 (± 25.23)

Notes:

[135] - Number of Subjects Analyzed at Weeks 4, 8 and 12:37, 35, 34.

[136] - Number of Subjects Analyzed at Weeks 4, 8 and 12:38, 35, 31.

[137] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 46.

[138] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[139]			
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 4	-13.7 (± 20.29)			

Week 8	-25.3 (± 20.74)			
Week 12	-34.2 (± 22.81)			

Notes:

[139] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Health Assessment Questionnaire – Disability Index (HAQ-DI) at Weeks 4, 8, and 12

End point title	Change From Baseline in the Health Assessment Questionnaire – Disability Index (HAQ-DI) at Weeks 4, 8, and 12[140]

End point description:

The HAQ-DI assesses the degree of difficulty that a subject has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2-3 items. For each question in the questionnaire, the level of difficulty is scored from 0 to 3 with 0 representing "no difficulty," 1 as "some difficulty," 2 as "much difficulty," and 3 as "unable to do." Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. This questionnaire was performed early in the clinic visit and before the subject had had extensive contact with site personnel and/or Investigator.

End point type	Secondary

End point timeframe:

Baseline Weeks 4, 8 and 12

Notes:

[140] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[141]	39[142]	50[143]	50[144]
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 4	-0.2 (± 0.46)	-0.2 (± 0.44)	-0.3 (± 0.40)	-0.2 (± 0.43)
Week 8	-0.4 (± 0.47)	-0.4 (± 0.54)	-0.4 (± 0.41)	-0.4 (± 0.56)
Week 12	-0.5 (± 0.47)	-0.5 (± 0.60)	-0.5 (± 0.48)	-0.5 (± 0.66)

Notes:

[141] - Number of Subjects Analyzed at Weeks 4, 8 and 12:37, 35, 34.

[142] - Number of Subjects Analyzed at Weeks 4, 8 and 12:38, 35, 31.

[143] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 46.

[144] - Number of Subjects Analyzed at Weeks 4, 8 and 12:49, 46, 45.

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[145]			
Units: units on a scale				
arithmetic mean (standard deviation)				
Week 4	-0.3 (± 0.49)			
Week 8	-0.5 (± 0.59)			

Week 12	-0.6 (± 0.59)			

Notes:

[145] - Number of Subjects Analyzed at Weeks 4, 8 and 12:47, 47, 45.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the 36 Item Short Form Health Survey (SF-36) Version 2 (Acute) 8 Domain Scores at Week 12

End point title	Change From Baseline in the 36 Item Short Form Health Survey (SF-36) Version 2 (Acute) 8 Domain Scores at Week 12[146]

End point description:

The SF-36 version 2 (acute) is a 36 item generic health status measure. It measures 8 general health domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. This was performed early in the clinic visit and before the subject had had extensive contact with site personnel and/or Investigator.

End point type	Secondary

End point timeframe:

Baseline and Week 12

Notes:

[146] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[147]	39[148]	50[149]	50[150]
Units: units on a scale				
arithmetic mean (standard deviation)				
Physical functioning domain	3.311 (± 11.5441)	4.885 (± 8.4161)	6.318 (± 8.6700)	5.412 (± 9.7871)
Role-physical domain	6.316 (± 9.7393)	5.773 (± 10.0629)	6.173 (± 8.5158)	6.151 (± 9.8448)
Bodily pain domain	7.840 (± 7.2950)	6.543 (± 9.3835)	7.280 (± 8.1633)	7.071 (± 9.6901)
General health domain	5.775 (± 6.7414)	5.531 (± 6.4448)	4.856 (± 6.5230)	4.916 (± 8.4424)
Vitality domain	8.717 (± 8.0179)	7.049 (± 9.9149)	7.354 (± 9.9326)	6.453 (± 10.2902)
Social function domain	5.061 (± 11.6125)	6.418 (± 11.6517)	6.430 (± 12.2952)	6.095 (± 12.1659)
Role-emotional domain	7.683 (± 11.2028)	4.396 (± 11.1492)	5.103 (± 12.5489)	6.730 (± 12.7335)
Mental health domain	7.497 (± 11.8826)	5.161 (± 11.7376)	5.661 (± 13.7839)	7.080 (± 12.9887)

Notes:

[147] - Number of Subjects Analyzed at Week 12: 34

[148] - Number of Subjects Analyzed at Week 12: 31

[149] - Number of Subjects Analyzed at Week 12: 46

[150] - Number of Subjects Analyzed at Week 12: 45

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[151]			
Units: units on a scale				
arithmetic mean (standard deviation)				
Physical functioning domain	7.322 (± 11.2219)			
Role-physical domain	6.734 (± 9.3707)			
Bodily pain domain	10.422 (± 8.6959)			
General health domain	7.046 (± 8.7992)			
Vitality domain	8.182 (± 8.7136)			
Social function domain	8.485 (± 9.2070)			
Role-emotional domain	6.646 (± 11.4190)			
Mental health domain	8.866 (± 10.4266)			

Notes:

[151] - Number of Subjects Analyzed at Week 12: 45

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Physical Component Score (PCS) and Mental Component Score (MCS) at Week 12

End point title	Change From Baseline in the Physical Component Score (PCS) and Mental Component Score (MCS) at Week 12[152]

End point description:

The SF 36 version 2 (acute) is a 36 item generic health status measure. It measures 8 general health domains. These domains can also be summarized as physical component score (PCS) and mental component score (MCS). This was performed early in the clinic visit and before the subject had had extensive contact with site personnel and/or Investigator.

End point type	Secondary

End point timeframe:

Baseline and Week 12

Notes:

[152] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[153]	39[154]	50[155]	50[156]
Units: units on a scale				
arithmetic mean (standard deviation)				
PCS	4.635 (± 7.8031)	5.728 (± 7.4254)	6.304 (± 7.6091)	5.212 (± 8.0162)
MCS	7.995 (± 11.5950)	5.241 (± 10.4860)	5.425 (± 13.6873)	6.749 (± 12.0657)

Notes:

[153] - Number of Subjects Analyzed at Week 12: 34

[154] - Number of Subjects Analyzed at Week 12: 31

[155] - Number of Subjects Analyzed at Week 12: 46

[156] - Number of Subjects Analyzed at Week 12: 45

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[157]			
Units: units on a scale				
arithmetic mean (standard deviation)				
PCS	7.476 (± 8.3473)			
MCS	7.759 (± 9.4263)			

Notes:

[157] - Number of Subjects Analyzed at Week 12: 45

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the European Quality of Life 5 Dimensions-3 Level (EQ-5D-3L) Score at Week 12

End point title	Change From Baseline in the European Quality of Life 5 Dimensions-3 Level (EQ-5D-3L) Score at Week 12[158]

End point description:

The EQ-5D-3L health state profile is a patient completed questionnaire designed to assess impact on health related quality of life in 5 domains: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Additionally, scores from the 5 domains might have been used to calculate a single index value, also known as a utility score. The validity and reliability of the EQ-5D-3L have been established in a number of disease states, including rheumatoid arthritis (RA). This questionnaire was performed early in the clinic visit and before the subject had had extensive contact with site personnel and/or Investigator. The form was checked by site staff for completeness.

End point type	Secondary

End point timeframe:

Baseline and Week 12

Notes:

[158] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[159]	39[160]	50[161]	50[162]
Units: units on a scale				
arithmetic mean (standard deviation)				
EQ visual analogue scale (VAS) score	13.265 (± 18.8540)	11.129 (± 24.6181)	11.913 (± 20.3795)	20.909 (± 24.5895)
Index value	0.132 (± 0.2030)	0.056 (± 0.1957)	0.118 (± 0.1661)	0.143 (± 0.2445)

Notes:

[159] - Number of Subjects Analyzed at Week 12: 34

[160] - Number of Subjects Analyzed at Week 12: 31

[161] - Number of Subjects Analyzed at Week 12: 45

[162] - Number of Subjects Analyzed at Week 12: 45

End point values	PF-06650833 400 mg			
Subject group type	Reporting group			
Number of subjects analysed	48[163]			
Units: units on a scale				
arithmetic mean (standard deviation)				
EQ visual analogue scale (VAS) score	20.778 (± 20.6792)			
Index value	0.190 (± 0.2201)			

Notes:

[163] - Number of Subjects Analyzed at Week 12: 45

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score at Week 12

End point title	Change From Baseline in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score at Week 12[164]

End point description:

The FACIT–F is a patient completed questionnaire consisting of 13 items that assess fatigue. Instrument scoring yields a range from 0 to 52, with higher scores representing better patient status (less fatigue). This questionnaire was performed early in the clinic visit and before the subject has extensive contact with site personnel and/or investigator.

End point type	Secondary

End point timeframe:

Baseline and Week 12

Notes:

[164] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: No statistical analysis was planned for this endpoint

End point values	Placebo	PF-06650833 20 mg	PF-06650833 60 mg	PF-06650833 200 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	39[165]	39[166]	50[167]	50[168]
Units: units on a scale				
arithmetic mean (standard deviation)	8.4 (± 8.76)	4.6 (± 10.92)	6.8 (± 8.33)	7.2 (± 11.45)

Notes:

[165] - Number of Subjects Analyzed at Week 12: 34

[166] - Number of Subjects Analyzed at Week 12: 31

[167] - Number of Subjects Analyzed at Week 12: 46

[168] - Number of Subjects Analyzed at Week 12: 45

End point values	PF-06650833 400 mg			

Subject group type	Reporting group			
Number of subjects analysed	48[169]			
Units: units on a scale				
arithmetic mean (standard deviation)	9.5 (± 9.68)			

Notes:

[169] - Number of Subjects Analyzed at Week 12: 45

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to PCD (about 21 months)

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. An event may be categorized as serious in 1 subject and as non-serious in another subject, or 1 subject may have experienced both a serious and non-serious event during the study. Total number at risk below refers to the number of subjects evaluable for SAEs or AEs.

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	21.0

Reporting groups

Reporting group title	Placebo

Reporting group description:

Subjects received 4 matching PF-06650833 modified release (MR) placebo tablets once daily (QD) and 1 matching tofacitinib placebo tablet twice a day (BID) in 12 weeks treatment period.

Reporting group title	Tofa 10 mg

Reporting group description:

Subjects received 4 matching PF-06650833 MR placebo tablets QD and 1 tofacitinib 5 mg tablet BID in 12 weeks treatment period.

Reporting group title	PF-06650833 20 mg

Reporting group description:

Subjects received 1 MR tablet of PF-06650833 20 mg and 3 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Reporting group title	PF-06650833 60 mg

Reporting group description:

Subjects received 3 MR tablets of PF-06650833 20 mg and 1 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Reporting group title	PF-06650833 200 mg

Reporting group description:

Subjects received 2 MR tablets of PF-06650833 100 mg and 2 matching PF-06650833 MR placebo tablets QD, 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Reporting group title	PF-06650833 400 mg

Reporting group description:

Subjects received 4 MR tablets of PF-06650833 100 mg QD and 1 matching tofacitinib placebo tablet BID in 12 weeks treatment period.

Serious adverse events	Placebo	Tofa 10 mg	PF-06650833 20 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 39 (2.56%)	1 / 43 (2.33%)	1 / 39 (2.56%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Humerus fracture			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Haemothorax			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haematoma			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatotoxicity			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	1 / 39 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Abscess limb			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 39 (0.00%)	1 / 43 (2.33%)	0 / 39 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	PF-06650833 60 mg	PF-06650833 200 mg	PF-06650833 400 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 50 (2.00%)	1 / 50 (2.00%)	3 / 48 (6.25%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Humerus fracture			
subjects affected / exposed	0 / 50 (0.00%)	1 / 50 (2.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1

deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Haemothorax			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haematoma			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatotoxicity			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess limb			
subjects affected / exposed	1 / 50 (2.00%)	0 / 50 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 50 (0.00%)	0 / 50 (0.00%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	Tofa 10 mg	PF-06650833 20 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 39 (25.64%)	8 / 43 (18.60%)	12 / 39 (30.77%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 39 (5.13%)	1 / 43 (2.33%)	0 / 39 (0.00%)
occurrences (all)	2	1	0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 39 (5.13%)	0 / 43 (0.00%)	1 / 39 (2.56%)
occurrences (all)	2	0	1
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 39 (0.00%)	1 / 43 (2.33%)	2 / 39 (5.13%)
occurrences (all)	0	1	2
Abdominal Pain			
subjects affected / exposed	2 / 39 (5.13%)	0 / 43 (0.00%)	0 / 39 (0.00%)
occurrences (all)	2	0	0
Nausea			
subjects affected / exposed	0 / 39 (0.00%)	1 / 43 (2.33%)	1 / 39 (2.56%)
occurrences (all)	0	1	1
Musculoskeletal and connective tissue disorders			
Rheumatoid arthritis			
subjects affected / exposed	2 / 39 (5.13%)	2 / 43 (4.65%)	4 / 39 (10.26%)
occurrences (all)	2	2	4
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	1 / 39 (2.56%)	2 / 43 (4.65%)	2 / 39 (5.13%)
occurrences (all)	1	5	3
Nasopharyngitis			
subjects affected / exposed	2 / 39 (5.13%)	3 / 43 (6.98%)	4 / 39 (10.26%)
occurrences (all)	2	3	4

Non-serious adverse events	PF-06650833 60 mg	PF-06650833 200 mg	PF-06650833 400 mg
Total subjects affected by non-serious			

adverse events			
subjects affected / exposed	11 / 50 (22.00%)	9 / 50 (18.00%)	11 / 48 (22.92%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 50 (2.00%)	2 / 50 (4.00%)	1 / 48 (2.08%)
occurrences (all)	1	3	1
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 50 (6.00%)	0 / 50 (0.00%)	1 / 48 (2.08%)
occurrences (all)	3	0	1
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 50 (0.00%)	1 / 50 (2.00%)	0 / 48 (0.00%)
occurrences (all)	0	1	0
Abdominal Pain			
subjects affected / exposed	0 / 50 (0.00%)	1 / 50 (2.00%)	1 / 48 (2.08%)
occurrences (all)	0	1	1
Nausea			
subjects affected / exposed	4 / 50 (8.00%)	2 / 50 (4.00%)	1 / 48 (2.08%)
occurrences (all)	4	2	1
Musculoskeletal and connective tissue disorders			
Rheumatoid arthritis			
subjects affected / exposed	2 / 50 (4.00%)	1 / 50 (2.00%)	3 / 48 (6.25%)
occurrences (all)	2	1	3
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	0 / 50 (0.00%)	2 / 50 (4.00%)	3 / 48 (6.25%)
occurrences (all)	0	2	3
Nasopharyngitis			
subjects affected / exposed	2 / 50 (4.00%)	1 / 50 (2.00%)	2 / 48 (4.17%)
occurrences (all)	2	1	3

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 October 2016	The protocol was amended in response to US regulatory feedback to increase the frequency of monitoring for urinary crystals and evidence of acute kidney injury by adding 3 study visits at Weeks 6, 10 and 14.
28 November 2016	The protocol was updated to allow prior (single) TNF experience after appropriate washout irrespective of inadequate response or due to lack of continued access; updated to clarify exclusion of subjects with alcohol or substance use and with prior active TB and to stipulate that live vaccines were not administered for at least 30 days after the last dose of study medication.
12 July 2017	Protocol summary and Sections 3, 4.1 and 5.7.1 were updated to clarify that prior use of parenteral MTX was permitted; Inclusion Criterion was updated to increase the recruitment age from 70 to 75 years old; Exclusion Criterion was updated to clarify TB and vaccination exclusion criteria, exclude recruitment of subjects with dermatomyositis and fibromyalgia, define the exclusion based on UACR as >=3 mg/mmol or >=30 mg/g, delete the subject eligibility based on the presence of atypical, needle like, urine crystals on urine microscopy.
08 August 2017	Protocol summary and section 3 were updated to clarify that methotrexate must have been dosed for at least 3 months to establish "inadequate response" not "lack of inadequate response; added the subject eligibility based on the presence of atypical, needle like, urine crystals on urine microscopy.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported